Success Metrics

Clinical Success Rate

77.8%

Based on 14 completed trials

Completion Rate

78%(14/18)

Active Trials

3(11%)

Results Posted

64%(9 trials)

Terminated

4(14%)

Phase Distribution

Ph phase_1

11%

Ph phase_3

Ph phase_4

39%

Ph phase_2

14%

Ph early_phase_1

Ph not_applicable

21%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution28 total trials

Early Phase 1First-in-human

2(7.1%)

Phase 1Safety & dosage

3(10.7%)

Phase 2Efficacy & side effects

4(14.3%)

Phase 3Large-scale testing

2(7.1%)

Phase 4Post-market surveillance

11(39.3%)

N/ANon-phased studies

6(21.4%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

63.6%

14 of 22 finished

Non-Completion Rate

36.4%

8 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(3)

Completed(14)

Terminated(8)

Other(3)

Detailed Status

Completed14

Withdrawn4

Terminated4

unknown3

Recruiting2

Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

77.8%

Most Advanced

Phase 4

Trials by Phase

Early Phase 12 (7.1%)

Phase 13 (10.7%)

Phase 24 (14.3%)

Phase 32 (7.1%)

Phase 411 (39.3%)

N/A6 (21.4%)

Trials by Status

withdrawn414%

completed1450%

unknown311%

active_not_recruiting14%

recruiting27%

terminated414%

Recent Activity

3 active trials

Showing 5 of 28

active_not_recruitingnot_applicable

Reprometabolic Syndrome Mediates Subfertility in Obesity

NCT02653092

recruitingnot_applicable

Intramyocellular Fatty Acid Trafficking in Insulin Resistance States - Effects of Intestinal Delivery of Lipids

NCT03818178

recruitingearly_phase_1

Clinical Trials (28)

Showing 20 of 28 trialsScroll for more

NCT02653092Not Applicable

Reprometabolic Syndrome Mediates Subfertility in Obesity

Active Not Recruiting

NCT03818178Not Applicable

Intramyocellular Fatty Acid Trafficking in Insulin Resistance States - Effects of Intestinal Delivery of Lipids

Recruiting

NCT04832009Early Phase 1

Reversing Glucose and Lipid-mediated Vascular Dysfunction

Recruiting

NCT03773237Not Applicable

Intralipid Versus SMOFlipid in HPN Patients

Completed

NCT01943409Phase 4

Intravenous Nutrition in Hospitalized Patients: Comparison of Two Oils

Completed

NCT04555044Phase 4

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion (Part A)

Completed

NCT03998709Phase 4

Effect of Fasting Free Fatty Acids and Fasting Glucose on 1st and 2nd Phase Insulin Secretion

Withdrawn

NCT02697201Early Phase 1

Dynamics of Muscle Mitochondria in Type 2 Diabetes (DYNAMMO T2D)

Completed

NCT02476994Phase 4

Pediatric Study to Evaluate Risk of Developing Essential Fatty Acid Deficiency When Receiving Clinolipid or Standard-of-Care Lipid Emulsion

Terminated

NCT04806425Phase 4

The Cardioprotective Effect of Intralipid in Decreasing the Ischemic Insults During Off-pump Coronary Artery Revascularization

Completed

NCT01679561Phase 4

Intralipid Therapy for Recurrent Implantation Failure and Recurrent Miscarriages: Is it a Hope or Myth?A Randomized Clinical Trial

Withdrawn

NCT00512629Phase 1

Cholestasis Prevention: Efficacy of IV Fish Oil

Completed

NCT02463812Not Applicable

Lipid Infusion Following Major Surgery

Withdrawn

NCT03127345Phase 2

Omega 3 Fatty Acid Treatment for Pediatric Musculoskeletal Health

Withdrawn

NCT02365285Phase 1

Racial Differences in Vagal Control of Glucose Homeostasis

Completed

NCT01520454Not Applicable

Effect of Increased Free Fatty Acids on Leptin Function

Completed

NCT02722902Not Applicable

Carnitine Infusion and Insulin Resistance

Terminated

NCT01788540Phase 4

Intralipid for Recurrent Miscarriage

Completed

NCT01585935Phase 4

Preventing Cholestasis Using SMOFLipid®

Completed

NCT03132779Phase 1

Intralipid Related Effect on NKcells in Patients With Unexplained Recurrent Spontaneous Abortion

Unknown

Drug Details

Intervention Type: DRUG
Total Trials: 28